Sutherlandioside DCAS# 1055329-49-1 |
Quality Control & MSDS
Number of papers citing our products
Chemical structure
| Cas No. | 1055329-49-1 | SDF | Download SDF |
| PubChem ID | N/A | Appearance | White powder |
| Formula | C36H58O9 | M.Wt | 634.9 |
| Type of Compound | Triterpenoids | Storage | Desiccate at -20°C |
| Solubility | Soluble in methan | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
| Description | Sutherlandioside D may exert anti-cancer effect by targeting Gli/Hh signaling. | |||||
Sutherlandioside D Dilution Calculator
Sutherlandioside D Molarity Calculator
| 1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
| 1 mM | 1.5751 mL | 7.8753 mL | 15.7505 mL | 31.501 mL | 39.3763 mL |
| 5 mM | 0.315 mL | 1.5751 mL | 3.1501 mL | 6.3002 mL | 7.8753 mL |
| 10 mM | 0.1575 mL | 0.7875 mL | 1.5751 mL | 3.1501 mL | 3.9376 mL |
| 50 mM | 0.0315 mL | 0.1575 mL | 0.315 mL | 0.63 mL | 0.7875 mL |
| 100 mM | 0.0158 mL | 0.0788 mL | 0.1575 mL | 0.315 mL | 0.3938 mL |
| * Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. | |||||
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
- Pilocarpine
Catalog No.:BCN9839
CAS No.:92-13-7
- 5-Methoxyflavone
Catalog No.:BCN9838
CAS No.:42079-78-7
- Isobutyl acetate
Catalog No.:BCN9837
CAS No.:110-19-0
- Urushiol (15:2)
Catalog No.:BCN9836
CAS No.:83258-37-1
- 6,7-Bis(benzyloxy)coumarin
Catalog No.:BCN9835
CAS No.:909-84-2
- BIX 01294 Trihydrochloride
Catalog No.:BCN9834
CAS No.:1392399-03-9
- Teupolioside
Catalog No.:BCN9833
CAS No.:143617-02-1
- Ethyl caproate
Catalog No.:BCN9832
CAS No.:123-66-0
- 28-Homobrassinolide
Catalog No.:BCN9831
CAS No.:82373-95-3
- Urushiol (15:1)
Catalog No.:BCN9830
CAS No.:35237-02-6
- 4,4'-Dimethoxychalcone
Catalog No.:BCN9829
CAS No.:2373-89-9
- Picrotoxinin
Catalog No.:BCN9828
CAS No.:17617-45-7
- Bletilol B
Catalog No.:BCN9841
CAS No.:147235-17-4
- Butyl acetate
Catalog No.:BCN9842
CAS No.:123-86-4
- Eugenol benzoate
Catalog No.:BCN9843
CAS No.:531-26-0
- Tryptanthrine
Catalog No.:BCN9844
CAS No.:13220-57-0
- 9-Hydroxy-O-senecioyl-8,9-dihydrooroselol
Catalog No.:BCN9845
CAS No.:31456-63-0
- Vitexin 7-glucoside
Catalog No.:BCN9846
CAS No.:35109-95-6
- Urushiol (15:3)
Catalog No.:BCN9847
CAS No.:83543-37-7
- Gardenin A
Catalog No.:BCN9848
CAS No.:21187-73-5
- alpha-Ionone
Catalog No.:BCN9849
CAS No.:127-41-3
- Flavonol
Catalog No.:BCN9850
CAS No.:577-85-5
- Helveticoside
Catalog No.:BCN9851
CAS No.:630-64-8
- Colchiceine
Catalog No.:BCN9852
CAS No.:477-27-0
Cycloartanol and Sutherlandioside C peracetate from Sutherlandia frutescens and their immune potentiating effects.[Pubmed:31393174]
Nat Prod Res. 2019 Aug 8:1-9.
A novel cycloartanol (1) and an acylated Sutherlandioside D (2) together with two known cycloartane derivatives, Sutherlandioside B (3) and Sutherlandioside A (4), were isolated from the aerial parts of Sutherlandia frutescens. The structures of these compounds were established by a combination of 1- and 2-D NMR techniques and further confirmed by high resolution ToF mass spectrometry (HRToFMS). Preliminary biological studies were also conducted to assess the activity of different plant extracts, fractions and compounds on cytokine expression. Compounds 1 and 2 prompted an increase in IL-6 expression while compound 4 showed a reduced IL-6 expression compared to the controls. Compound 1 is an effective suppressor of IL-10 expression. The plant compounds inhibited the expression of the two cytokines, IL-10 and TNFalpha. The results of the assays suggested that some components in the plant extract influence the immune system by suppressing the expression of IL-6, IL-10 and TNFalpha.
Inhibition of Gli/hedgehog signaling in prostate cancer cells by "cancer bush" Sutherlandia frutescens extract.[Pubmed:26377232]
Cell Biol Int. 2016 Feb;40(2):131-42.
Sutherlandia frutescens is a medicinal plant, traditionally used to treat various types of human diseases, including cancer. Previous studies of several botanicals link suppression of prostate cancer growth with inhibition of the Gli/hedgehog (Gli/Hh) signaling pathway. Here we hypothesized the anti-cancer effect of S. frutescens was linked to its inhibition of the Gli/Hh signaling in prostate cancer. We found a dose- and time-dependent growth inhibition in human prostate cancer cells, PC3 and LNCaP, and mouse prostate cancer cell, TRAMP-C2, treated with S. frutescens methanol extract (SLE). We also observed a dose-dependent inhibition of the Gli-reporter activity in Shh Light II and TRAMP-C2QGli cells treated with SLE. In addition, SLE can inhibit Gli/Hh signaling by blocking Gli1 and Ptched1 gene expression in the presence of a Gli/Hh signaling agonist (SAG). A diet supplemented with S. frutescens suppressed the formation of poorly differentiated carcinoma in prostates of TRAMP mice. Finally, we found Sutherlandioside D was the most potent compound in the crude extract that could suppress Gli-reporter in Shh Light II cells. Together, this suggests that the S. frutescens extract may exert anti-cancer effect by targeting Gli/Hh signaling, and Sutherlandioside D is one of the active compounds.
